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Enzymes that bind and process ubiquitin, a small 76-amino-acid protein, have been
recognized as pharmacological targets in oncology, immunological disorders, and
neurodegeneration. Mass spectrometry technology has now reached the capacity to
cover the proteome with enough depth to interrogate entire biochemical pathways
including those that contain DUBs and E3 ligase substrates. We have recently
characterized the breast cancer cell (MCF7) deep proteome by detecting and quantifying
∼10,000 proteins, and within this data set, we can detect endogenous expression of
65 deubiquitylating enzymes (DUBs), whereas matching transcriptomics detected 78
DUB mRNAs. Since enzyme activity provides another meaningful layer of information
in addition to the expression levels, we have combined advanced mass spectrometry
technology, pre-fractionation, and more potent/selective ubiquitin active-site probes with
propargylic-based electrophiles to profile 74 DUBs including distinguishable isoforms for
5 DUBs in MCF7 crude extract material. Competition experiments with cysteine alkylating
agents and pan-DUB inhibitors combined with probe labeling revealed the proportion of
active cellular DUBs directly engaged with probes by label-free quantitative (LFQ) mass
spectrometry. This demonstrated that USP13, 39, and 40 are non-reactive to probe,
indicating restricted enzymatic activity under these cellular conditions. Our extended
chemoproteomics workflow increases depth of covering the active DUBome, including
isoform-specific resolution, and provides the framework for more comprehensive
cell-based small-molecule DUB selectivity profiling.
Keywords: deubiquitylating enzymes, mass spectrometry, proteomics, chemical biology, ubiquitin specific
proteases, isoforms
INTRODUCTION
Ubiquitin (Ub) is a conserved, globular protein consisting of 76 amino acids that can be attached
to proteins either in a mono- or polymerized form, impacting on their activity, localization,
interactome, and turnover. The covalent attachment of Ub, most frequently to a ε-NH2 lysine side
chain of protein substrates, is catalyzed by the sequential action of three enzymes: E1 activating
enzyme, E2 conjugating enzyme, and E3 ligase (Hershko and Ciechanover, 1998). Polymers of Ub
can be formed by the addition of one or more monomers to a previously substrate-attached Ub
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molecule. These chains provide a code of functional
modulations including protein degradation and cellular
signaling (Komander and Rape, 2012). Poly-Ub chains can
also include Ub-like modifiers (UBLs) (Cappadocia and
Lima, 2018) and posttranslational modifications (PTMs)
that increase the biological complexity of ubiquitylation
(Swatek and Komander, 2016).
Polymerization of Ub is a reversible process carried out by
deubiquitylating enzymes (DUBs) that catalyze hydrolysis of
Ub–substrate isopeptide bonds (Komander et al., 2009). To date,
there are 102 human DUBs that have been grouped into eight
different sub-families (Komander et al., 2009; Fraile et al., 2012):
Ub-specific proteases (USPs), Ub carboxy-terminal hydrolases
(UCHs), ovarian tumor domain containing proteases (OTUs),
Machado–Joseph disease protein domain proteases (MJDs or
Josephins), JAMM/MPN domain-associated metallopeptidases
(JAMMs), motif interacting with Ub-containing novel DUB
(MINDYs) (Abdul Rehman et al., 2016), the less studied
monocyte chemotactic protein-induced protein (MCPIPs)
(Kolattukudy and Niu, 2012), and the recently discovered
Zn-finger and UFSP domain protein (ZUFSP) (Haahr et al.,
2018; Hermanns et al., 2018; Hewings et al., 2018). Most DUBs
(∼80) are classified as cysteine proteases with the exception of
JAMM metallopeptidases and inactive (pseudo) DUBs (Nijman
et al., 2005; Komander et al., 2009). DUBs have emerged as
key enzymes for deciding the fate of most intracellular proteins
regarding their function and lifespan. Highly selective and
potent DUB inhibitors are now emerging (Kategaya et al., 2017;
Lamberto et al., 2017; Turnbull et al., 2017; Gavory et al., 2018;
Harrigan et al., 2018; Clague et al., 2019), which, in addition to
PROteolysis-TArgeting chimeras (PROTACS) (Mullard, 2019),
are paving the way to explore the Ub system in drug discovery
development programs by modulating the turnover of key
targets in the context of cancer, dementia, and inflammation
(Pinto-Fernandez and Kessler, 2016; Harrigan et al., 2018). DUB
inhibitor development has been accelerated by the application
of Ub activity-based probes (ABPs) (Altun et al., 2011; Turnbull
et al., 2017). ABPs contain a specificity motif that targets them to
the desired enzyme/class of enzymes and a chemical moiety that
reacts covalently with the active site of the enzyme. This has been
applicable to study proteases that have a nucleophilic active site,
mainly serine hydrolases and cysteine peptidases (Sanman and
Bogyo, 2014), but also metalloproteases (Nury et al., 2013; Amara
et al., 2018). For DUBs, many different probe architectures have
been generated and tested with different selectivity toward
DUBs, with those using a molecule of Ub as specificity motif
being the more popular ones (Borodovsky et al., 2001, 2002,
2005; Hemelaar et al., 2004). However, di-Ub ABPs mimicking
the different poly-Ub linkages have been generated and studied
(McGouran et al., 2013), with the linear di-Ub being highly
selective toward OTULIN (Weber et al., 2017). Finally, thanks
to the utilization of a DUB inhibitor as specificity motif, Ward
et al. (2016) managed to synthesize a permeable ABP reactive
with a number of DUBs. Different C-terminal chemical moieties
enabling Michael additions and nucleophilic displacements
have been explored, and more recently, alkynes that react via a
radical-based mechanism (Ekkebus et al., 2013; Hewings et al.,
2017). To determine the subset of DUBs that directly react
with probe in addition to binding, DUB-probe reaction centric
probes were generated that enrich for Cys-reactive peptides after
enzymatic digestion to map covalent sites within reactive DUBs
(Hewings et al., 2018). Despite these advances, it is unclear to
what extent the entire range of endogenous DUBs expressed that
are active in cells are captured.
To address this, we have developed an advanced “activitomics”
workflow and compared it against the DUB transcriptome
and proteome expressed in MCF7 breast cancer cells. We
discriminate between DUBs reactive to probe and non-reactive
enzyme species through competition at the enzyme’s active-
site cysteine combined with quantitative chemoproteomics. The
range covered by the cellular DUB activitome, transcriptome
(mRNA), and deep proteome (protein) is comparable, revealing
an extended landscape of the cellular DUBome.
We acknowledge that it is challenging to compare proteomics
data because instrumentation, methods, and software are in
constant evolution and all three are quite heterogeneous from lab
to lab. In this particular study, we identified 74 DUBs whereas
most previous studies reported on between 20 and 40 DUBs. A
recent study by IngridWertz’ group reported the identification of
61 DUBs (Hewings et al., 2018). Therefore, our study represents
the most comprehensive coverage reported so far.
MATERIALS AND METHODS
Contact for Reagent and Resource Sharing
Further information and requests for resources and
reagents should be directed to and will be fulfilled by the
corresponding authors, BK (benedikt.kessler@ndm.ox.ac.uk)
and AP-F (adan.pintofernandez@ndm.ox.ac.uk).
Cell Lines and Reagents
Commercially purchased MCF7 (ATCC Nr HTB-22) cells were
cultured in DMEM medium (GIBCO) supplemented with 10%
fetal calf serum (FCS; GIBCO), 100 U/ml penicillin (SIGMA),
and 100µg/ml streptomycin (SIGMA) and maintained at 37◦C
in a humidified atmosphere at 5% CO2. Other reagents used in
this study are listed in Table 1.
Ub-Based ABP Synthesis
The construct pTYB-HAUb, comprising the sequences of the
human Ub (lacking Gly 76), an intein and a chitin binding
domain, plus an HA tag, was used to synthesize HAUb75-MESNa
as described previously (Borodovsky et al., 2002). Briefly, Ub–
intein–chitin domain fusion protein was expressed in Escherichia
coli (18 h induction with 0.4mM IPTG at 17◦C). Cell pellets
were resuspended in 50mM HEPES, pH 7.4, 150mM NaCl,
and 0.5mM TCEP and lysed in a high-pressure homogenizer.
The cleared cell extract was loaded onto a 15ml chitin bead
(New England Biolabs) column at a flow rate of 0.5 ml/min. The
column was washed with 60ml of lysis buffer followed by 25ml
of lysis buffer containing 50mM β-mercaptoethanesulfonic acid
sodium salt (MESNa) and incubated overnight at 37◦C for the
induction of on-column cleavage. HAUb75-MESNa thioester was
eluted with 25ml of lysis buffer and concentrated: approximately
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TABLE 1 | Cell lines and reagents.
Reagent or resource Source Identifier
ANTIBODIES
Mouse monoclonal antibody
HA (12CA5)
Roche #11583816001
USP7 pAb Enzo #BML-PW0540-0100
GAPDH loading control
antibody (GA1R)
Invitrogen #MA5-15738
Monoclonal
Anti-HA-Agarose antibody
produced in mouse
SIGMA #A2095-1ML
CHEMICALS, KITS, ENZYMES, AND OTHERS
Trypsin (TPCK-treated) Worthington #LS003740
Acid-washed glass beads SIGMA # G4649
PierceTM BCA Protein
Assay Kit
Thermofisher #23225
Criterion TGX Gel, 4–15%,
18-well
Bio-Rad #5671084
Sep-Pak C18 Plus Short
Cartridge, 360mg Sorbent
per Cartridge, 55–105µm
Particle Size
Waters # WAT020515
Chitin resin New England
Biolabs
#S6651L
PD-10 columns GE
Healthcare
#17-0851-01
2-Bromoethylamine SIGMA #B65705-25G
Propargylamine SIGMA #P50900-5G
EXPERIMENTAL MODELS: CELL LINES
MCF7 cells ATCC HTB-22
Software and Algorithms
MaxQuant Software (version
1.5.2)
Open source http://www.coxdocs.org/
doku.php?id=maxquant:
start
Perseus Software (version
1.6.2.3)
Open source http://www.coxdocs.org/
doku.php?id=perseus:
start
Prism 8 GraphPad https://www.graphpad.
com/scientific-software/
prism/
2.5mg of protein was recovered from a 1-L culture. The N-
terminal Met of the HA-tag was frequently processed off during
expression, resulting in a mixture of two proteins that behaved
identically in labeling experiments.
To synthesize the HA-UbC2Br or HA-UbPA probes, 0.2mM
of 2-bromoethylamine or 250mM propargylamine was added to
a solution of HAUb75-MESNa (1–2 mg/ml) in 500 µl of column
buffer, respectively. pH was carefully adjusted to 8 with NaOH,
and after 20min shaking at 1,400 rpm, at room temperature, 100
µl of 2.0M aqueous HCl was added and the resultant reaction
mixture was promptly transferred to a PD10 gravity column for
buffer exchange, according to the manufacturer’s instructions.
The probe was then aliquoted and frozen at −80◦C for
storage (no significant deterioration is observed for several
months of storage except for HA-UbC2Br, which is prone to
hydrolysis). All HA-Ub-derived probes were analyzed by liquid
chromatographymass spectrometry (LC-MS) using a 1290UPLC
(Agilent) coupled to a 6560 quadrupole time-of-flight (QToF)
mass spectrometer (Agilent) to monitor the reaction and the
product detected by [M+H]+ = 10,197.6221, with >90% purity.
Preparation of Cell Extracts and Western
Blotting
Protein extracts were prepared as follows: Cells were washed
with ice-cold PBS and collected into a centrifuge tube in either
glass beads lysis buffer (GBL: 50mM Tris, pH 7.5, 5mM MgCl2,
0.5mM EDTA, and 250mM Sucrose) or glass beads lysis buffer
plus 0.2% NP-40 (GBLN). One volume of acid-washed glass
beads (Sigma Aldrich, G4649) per 2–3 volumes of ice-cold glass
bead buffer (+1mM DTT) was added to the tube containing
the cells and buffer followed by vortexing (10 times in 30 s
bursts, returning the samples to the ice for 1–2min in between)
and centrifugation (14,000 g, 4◦C, 25min) in order to pellet
the glass beads, nuclei, and membranes. The supernatant was
carefully transferred to fresh Eppendorf tubes and the pellets
were discarded. The protein concentration was determined via
the Thermo BCA protein assay kit. For Western blotting, 25
µg of protein was then fractionated on Tris–glycine SDS-
PAGE gradient (4–15% acrylamide) gels, transferred onto PVDF
membranes, and detected with the indicated antibodies using a
LI-COR detection system.
DUB Activity-Based Profiling
At least 500 µg of cell extract (corresponding to approximately
1× 107 cells) in 300µl of GBL buffer containing 1mMDTTwere
utilized for the ABP pulldowns. When profiling a DUB inhibitor,
the inhibitor should be added at this point to the desired final
concentration and incubated at 37◦C for 1 h. Then,∼10µg of the
HA-Ub-based ABPs were added per 500 µg of sample (Note: this
will vary depending on the reactivity of the probe batch and type
and may require optimization for complete labeling of the DUB
of interest) and incubated at 37◦C for 45min. The reaction was
quenched by the addition of SDS to 0.4% (24 µl of a 5% stock per
300 µl) and NP-40 (or IGEPAL CA-630 substitute) to 0.5% (15
µl of a 10% stock per 300 µl), and samples were diluted to 1ml,
0.5 mg/ml, by the addition of 661 µl of NP-40 lysis buffer [pH
7.4, 50mM Tris, 0.5% (v/v) NP-40, 150mM NaCl, and 20mM
MgCl2]. Fifty microliters (25 µg) of sample was aliquoted and
denatured by boiling in SDS Laemmli sample buffer for control
blotting to assess IP efficiency. To bind and pull down DUB–
ABP complexes, 150 µl of anti-HA-Agarose slurry (previously
washed four times with NP-40 lysis buffer) was added to the
samples and incubated on a rotator overnight at 4◦C. After a
first centrifugation step (2,000 g, 4◦C, 1min), beads were washed
four times with 500 µl of NP-40 lysis buffer. Protein complexes
were eluted by boiling beads in 110 µl of 2× SDS Laemmli
sample buffer and 10% were analyzed by Western blotting after
SDS-PAGE, as well as lysate controls.
Mass Spectrometry Experiments (Sample
Preparation and Fractionation)
DUB-probe immunoprecipitated sample eluates were diluted
to 175 µl with ultra-pure water and reduced with 5 µl of
DTT (200mM in 0.1M Tris, pH 7.8) for 30min at 37◦C.
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Samples were alkylated with 20 µl of iodoacetamide (100mM in
0.1M Tris, pH 7.8) for 15min at room temperature (protected
from light), followed by protein precipitation using a double
methanol/chloroform extraction method (Wessel and Flugge,
1984). Protein samples were treated with 600 µl of methanol,
150 µl of chloroform, and 450 µl of water, followed by vigorous
vortexing. Samples were centrifuged at 17,000 g for 3min,
and the resultant upper aqueous phase was removed. Proteins
were pelleted following the addition of 450 µl of methanol
and centrifugation at 17,000 g for 6min. The supernatant was
removed, and the extraction process was repeated. Following
the second extraction process, precipitated proteins were re-
suspended in 50 µl of 6M urea and diluted to <1M urea with
250 µl of 20mM HEPES (pH 8.0) buffer. Protein digestion was
carried out by adding trypsin (from a 1 mg/ml stock in 1mM
HCl) to a ratio 1:100, rocking at 12 rpm and room temperature
overnight. Following digestion, samples were acidified to 1%
trifluoroacetic acid and desalted on C18 solid-phase extraction
cartridges (SEP-PAK plus, Waters), dried, and re-suspended in
2% acetonitrile and 0.1% formic acid for analysis by LC-MS/MS
as described below.
Off-line high-pH reverse-phase prefractionation was
performed in a similar fashion as in Davis et al. (2017). Briefly,
digested material was fractionated using the loading pump of
a Dionex Ultimate 3000 HPLC with an automated fraction
collector and a Waters Acquity UPLC Peptide BEH C18, 300
Å, 1.7µm, 1mm × 100mm (part no. 186005593) column over
a 65min gradient using basic pH reverse-phase buffers (A:
water, pH 10 with ammonium hydroxide; B: 90% acetonitrile,
pH 10 with ammonium hydroxide). The gradient consisted
of a 15min wash with 2% B, then increasing to 35% B over
30min, with a further increase to 95% B in 0.1min, followed by
a 9.9min wash at 95% B and then returning to 2% in 0.1min,
followed by re-equilibration at 2% B for 9.9min, all at a flow
rate of 100 µl/min with fractions collected every 1min from
0 to 60min. One hundred microliters of the fractions was
dried and resuspended in 20 µl of 2% acetonitrile/0.1% formic
acid for analysis by LC–MS/MS. Fractions were loaded on
the LC–MS/MS following concatenation of 60 fractions into
10, combining fractions in a 10-fraction interval (F1 + F11
+ F21 + F31 + F41 + F51. . . to F10 + F20 + F30 + F40 +
F50+ F60).
Liquid Chromatography–Mass
Spectrometry/Mass Spectrometry
(LC-MS/MS)
LC-MS/MS analysis was performed using a Dionex Ultimate
3000 nano-ultra high-pressure reverse-phase chromatography
coupled on-line to a Q Exactive HF mass spectrometer
(Thermo Scientific) as described previously (Fye et al., 2018).
In brief, samples were separated on an EASY-Spray PepMap
RSLC C18 column (500mm × 75µm, 2µm particle size,
Thermo Scientific) over a 60min gradient of 2–35% acetonitrile
in 5% dimethyl sulfoxide (DMSO), 0.1% formic acid at
250 nL/min. MS1 scans were acquired at a resolution
of 60,000 at 200 m/z and the top 12 most abundant
precursor ions were selected for high collision dissociation
(HCD) fragmentation.
Transcriptomics Analysis of MCF7 Cells
A total of 5 × 108 MCF7 cells were grown to ∼90%
confluency as described above, harvested by centrifugation
at 1,500 rpm, and resuspended in ice-cold PBS, centrifuged
again, and pellets were kept at −20◦C until analysis. RNA
was extracted from cell pellets using the RNeasy Mini Kit
(QIAGEN) according to the manufacturer’s instructions. mRNA
material was further enriched using poly-T oligo column
(Manufacturer). The quality of the mRNA was checked by
OD260/280nm ratio and found to be ∼2. The cDNA library was
prepared using a standardized protocol followed by paired end
sequencing using a HiSeq4000 platform (Illumina) at the Oxford
Genomics Center (Wellcome Trust Center for Human Genetics,
Oxford, UK).
Transcriptomics and Proteomics Data
Analysis
For the analysis of transcriptomics data, FASTQ files were
converted to Binary-sequence Alignment Format (BAM) files
using HISAT2 (v2.1.0) and Samtools (v1.3). Subsequently, BAM
files were imported into Perseus software (v1.6.0.2) and genome
annotation was performed using the Human Fasta cDNA
database (http://www.ensembl.org). Reads per kilo per million
(RPKM) values were calculated by a normalization step dividing
by the sum (Normalization → Divide), followed by dividing
normalized values by gene length, multiplying by 109, and taking
the log2 values (Table S1).
For the analysis of proteomics data, the DUB proteome in
MCF7 cells was assessed by interrogating the quantified iBAQ
values taken from our previous study (Davis et al., 2017) that were
then matched to the MCF7 transcriptome using Perseus software
(v1.6.0.2) (Table S2). For the DUB activitome, all raw MS data
files from theHA-IP and high-pH fractionation experiments were
analyzed in a combined fashion using MaxQuant (v1.5.5.1) and
searched against the UniProt Human database (92,954 entries).
Intensity values were used to compare against the DUB proteome
and transcriptome (Table S3). Zero values were replaced with the
value of 1 to allow for displaying the data using scatter plots
as shown in Figures 1C, 7. For searches of PTMs, in particular
the HA-UbPA probe adduct (112.06 Da) on cysteine residues,
each raw MS data file obtained per high-pH fraction analyzed
by LC-MS/MS was analyzed using PEAKS software (v 8.5; we
used a 1% FDR at protein and peptide level in PEAKS with
the −10LogP values of 40 for protein and 23.2 for peptide
positive identification) and searched against theUniProt database
(UPR_HomoSapiens_20170215). Search parameters were the
following: parent mass error tolerance: 10 ppm; fragment mass
error tolerance: 0.05 Da; precursor mass search: monoisotopic;
enzyme: trypsin; missed cleavages: 2; variable modifications
(PEAKS PTM, only the most common listed): deamidation
(NQ), oxidation (M), carbamidomethylation (C), acetylation (K),
acetylation (N-term), PA Probe adduct (C), maximal variable
PTM per peptide: 3.
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FIGURE 1 | DUB transcriptome and proteome in MCF7 breast cancer cells. (A) Transcriptome analysis (single experiment data) listing all quantified mRNAs as reads
per Kilobase per million (RPKM) values in descending values. mRNAs encoding DUBs are indicated according to their families: 56 USPs (red), 5 UCHs (dark green), 16
OTUs (blue), 11 JAMMs (purple), 4 MINDYs (yellow), 4 JOS (light green), and 1 ZUP (black). (B) Proteome analysis (single experiment data) listing all quantified proteins
as intensity-based absolute quantitation (iBAQ) abundances in descending values. DUBs are indicated and colored based on sub-families as stated above. (C)
Scatter Plot showing mRNA (transcriptome, X-axis) and protein (proteome, Y-axis) levels of DUBs (indicated in colors according to sub-families).
Generation of the Human DUB
Phylogenetic Tree
Genes included in this analysis:
[(CYLD, PAN2, USP17L24, USP1, USP2, USP3_H0YMI,
USP3_Q9Y6I, USP4, USP5, USP6, USP7, USP8, USP9X,
USP10, USP9Y, USP11, USP12, USP13, USP14, USP15,
USP16, USP17L1, USP17L2, USP18, USP19, USP20, USP21,
USP22, USP24, USP25, USP26, USP27X, USP28, USP29,
USP30, USP31, USP32_K7EK, USP32_Q8NF, USP33, USP34,
USP35, USP36, USP37, USP38, USP39, USP40, USP41, USP42,
USP43, USP44, USP45, USP46, USP47, USP48, USP49, USP50,
USP51, USP53, USP54), (BRCC3, COPS5, COPS6, EIF3F,
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EIF3H, MPND, MYSM1, PRPF8, PSMD7, PSMD14, STAMBP,
STAMBPL1), (ALG13, OTUB1, OTUB2, OTUD1, OTUD3,
OTUD4, OTUD5, OTUD6A, OTUD6B, OTUD7A, OTUD7B,
OTULIN, OTULINL, TNFAIP3, VCPIP1, YOD1, ZRANB1),
(UCHL1, UCHL3, UCHL5, BAP1), (ATXN3, ATXN3L, JOSD1,
JOSD2), (MINDY1, MINDY2, MINDY3, MINDY4)].
The full-length protein sequences for each DUB were
extracted from UniProt (https://uniprot.org/). The canonical
sequence for each DUB was used as it was determined
by UniProt. The protein alignment was performed using
MUSCLE (multiple sequence alignment with high accuracy and
high throughput). Finally, a constraint ML phylogenetic tree
was generated by RAxML (https://raxml-ng.vital-it.ch/#/). The
constraint tree was created by including DUBs into the seven
known families. The LG Substitution matrix was used. The
best fit model tree was further designed initially in the iTOL
INTERACTIVE TREE OF LIFE (https://itol.embl.de/) where
branched length was ignored, and an unrooted tree style was
FIGURE 2 | Ub-PA probe chemistry extends DUBome activity-based profiling. (A) Titration of HA-UbC2Br (left panel) and HA-UbPA probe (right panel) in MCF7 breast
cancer cell extracts, followed by SDS-PAGE separation and analysis by anti-HA immunoblotting. Bands correspond to either DUB-probe or E3 ligase-probe adducts
as indicated [based on (Altun et al., 2011) and this study]. (B) Left panel: Chemoproteomics workflow for profiling the active DUBome. HA-UbC2Br or HA-UbPA probe
is incubated with MCF7 breast cancer cell extracts, followed by anti-HA immunoprecipitation, elution, in-solution trypsin digestion, and label-free quantitative analysis
(LFQ) by LC-MS/MS. Right panel: Comparison of HA-UbC2Br and HA-UbPA immunoprecipitated DUBs analyzed by SDS-PAGE and anti-HA, anti-USP7 (positive
control), and anti-GAPDH (loading control) immunoblotting.
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formed. Finally, the Adobe Illustrator software was then used to
finalize the tree.
Data Availability
MCF7 RNA-seq data have been submitted to GEO with the
accession number GSE134954.
The mass spectrometry proteomics data have been deposited
to the ProteomeXchange Consortium via the PRIDE (Perez-
Riverol et al., 2019) partner repository with the data set
identifier PXD014391.
RESULTS AND DISCUSSION
DUB mRNA and Protein Expression
Topology in MCF7 Breast Cancer Cells
To set a baseline, we wished to interrogate the number of DUBs
and their abundance at the mRNA and protein level in MCF7
cells, a cell line originally established from the pleural effusion
of a 69 year-old woman with metastatic disease (Brooks et al.,
1973) and used for breast cancer research for more than 40 years
(Comsa et al., 2015). Based on previous studies from our lab
and others (Borodovsky et al., 2002; Altun et al., 2011; Turnbull
et al., 2017), it appears that MCF-7 has a similar DUB profile
to other immortalized cell lines but there are specific DUBs
that are expressed in some cell lines and not in MCF-7. For
instance, neuronal cells have high levels of active UCHL-1 [also
seen to vary considerably in immortalized B-cell lines (Ovaa et al.,
2004)], and HEK293 cells (human embryonic kidney) express
a recently discovered DUB called ZUP1 (ZUFSP), whereas we
were not able to detect either, UCHL-1 or ZUP1, in MCF-
7 cells. Therefore, we feel that using the immortalized breast
cancer cell line MCF7, we represent most of the endogenous
DUBome. To obtain maximal depth, we performed RNA-Seq
and pre-fractionation-based deep proteomics, resulting in 21,352
transcripts and 13,728 identified protein groups from which
8,949 were assigned to genes (Davis et al., 2017). In these data sets,
we detected 78DUBs by RNA-seq (76% out of 102 assignedDUBs
in the human genome) (Figure 1A) and 65 DUBs at the protein
level (corresponding to 53 genes) (Figure 1B). Interestingly, the
DUBs MINDY1/3/4, ZUFSP, UCHL1, and alternative isoforms
of OTU and USP subsets were detected only at the mRNA level,
whereas others such as USP35, USP30, USP16, UCHL-3, and up
to 12 DUBs were present as proteins only (Figure S1), suggesting
distinct regulatory mechanisms and/or stability of their mRNA
vs. protein. Generally, global mRNA expression levels poorly
correlated with protein levels (Figure 1C), a trait observed in
previously reported studies (Maier et al., 2009; Schwanhausser
et al., 2011; Wang et al., 2019).
FIGURE 3 | Full DUBome coverage by advanced chemoproteomics. Scatter Plot showing enrichment of DUBs upon labeling and isolation of HA-UbPA activity-based
probe pulldown and quantitative analysis by mass spectrometry (concatenation of 60 fractions into 10). X-axis—no probe; Y-axis—with probe. The experimental
workflow is shown on the top. The graph inclusion shows the number of DUBs captured by the HA-UbPA probe with (single experiment data) and without (technical
triplicates) high-pH prefractionation post-HA-IP and digestion.
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Reactivity of Different Ub Probes Affects
Dubome Selectivity
To better gauge DUB cellular function, we aimed to match DUB
expression with their activity at a global level using an improved
activity-based protein profiling (ABPP)-based workflow (Altun
et al., 2011; Turnbull et al., 2017). A limitation for these ABPP
studies has been the proteomic technique by itself as well as
some DUB targeting selectivity based on the chemical moiety
of the probe (Borodovsky et al., 2002). Recently, more sensitive
mass spectrometry and the use of reactive-site-centric Ub probes
with a vinyl sulfone (VS) or a vinyl methyl ester (VME) revealed
less DUB selectivity dependent on the chemical group used,
but has also shown that some of them tend to react with non-
catalytic cysteine residues, whereas propargylamide (PA)-based
probes seem to react more specifically with catalytic cysteines
(Hewings et al., 2018). This could be due to the unconventional
reactivity of the alkyne in the propargylamide with the thiol
group on the catalytic cysteine, which is unusual as electron-rich
alkynes are generally poor electrophiles. UbPA reacts with DUB
cysteines via direct addition to the terminal alkyne to give a vinyl
thioether through possible radical-based intermediates (Ekkebus
et al., 2013). HA-UbPA is reported to be highly DUB selective,
with the exception of the additional labeling of the E3 Ub ligase
HUWE1 (Ekkebus et al., 2013). We decided to compare side by
side Ub probes with the different reactivities by performing an
ABP assay in MCF7 cell lysates, UbPA (direct addition), UbVME
(conjugate addition), and UbC2Br (nucleophilic displacement)
(Figure S2A). As previously described, the UbC2Br probe has a
different reactivity profile to cellular DUBs when compared to the
VME probe (Borodovsky et al., 2002), in particular with the band
corresponding to OTUB1 (theoretical molecular weight: 31,284
Da, ∼37 kDa marker). On the other hand, USP14 (theoretical
molecular weight: 56,069 Da, below the 75 kDa marker) is
labeled more efficiently by UbVME as compared to UbC2Br. We
FIGURE 4 | Mapping direct Ub–probe DUB adducts by mass spectrometry. LC-MS/MS analysis of HA-UbPA-labeled DUBs isolated from MCF7 breast cancer cell
extracts. Peptide mapping using PEAKS analysis reveals direct cysteine–probe adducts (light blue boxes—P) for the DUBs UCHL3, OTUB1, OTUD3, OTUD4, and
OTUD6B. The corresponding MS/MS fragmentation spectra for assigning the Cys–UbPA–probe adducts are listed in Figures S3A–S3E.
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concluded that the UbPA probe seems to react more efficiently
with all cellular DUBs as judged by the visualized bands. To
further compare the two probes with the broadest labeling
profiles, we performed an ABPP by immunoprecipitating HA-
tagged UbPA and UbC2Br probes after labeling MCF7 crude
extracts, confirming the greater breadth of cellular DUB labeling
with the UbPA probe (Figure 2A). We also analyzed probe-
captured material by quantitative mass spectrometry (Figure 2B
and Table S4). Both Western blotting and mass spectrometry
results confirm the superior reactivity of the UbPA probe over
the UbC2Br (Figure 2A and Figure S2A), being able to identify
44 DUBs with the former and 37 with the latter (Figure S2B and
Table S4).
Improved ABP Using Advanced Proteomics
Methodology Expands the Dubome
Since the number of identified DUBs using UbPA in ABPP,
although improved, was still not in the range of DUBs expressed
in MCF7 cells (Figure 1), we decided to explore a more advanced
proteomic methodology in order to expand the active DUBome.
To this end, we implemented a high-pH pre-fractionation in
our classical ABPP workflow after the digestion step (Figure 2B)
in order to reduce the sample complexity in an orthogonal
dimension prior to LC-MS/MS analysis (Wang et al., 2011; Davis
et al., 2017). This yielded an increase in the number of DUB
identifications from 39 to 74 protein groups, corresponding to
65 DUB genes, greatly expanding the number observed in the
conventional ABPP-MS workflow (>92%) [Figure 3 (inset) and
Figure S2B]. The number of DUBs detectable via the ABP-MS
assay is now comparable to the number of expressed DUBs in the
same cell line.
Discrimination Between Active Dubs vs.
Non-active Dubs
To gain more detailed information about cellular DUB activity
captured by our ABPP assay, it was necessary to determine
which fraction of enzymes directly reacted with probe and were
not enriched only through affinity binding. We addressed this
through two experimental approaches. First, we interrogated our
data for the presence of Ub-probe adducts, which confirmed
the direct reactivity of UCHL3 Cys95, OTUB1 Cys91, OTUD3
Cys76, OTUD4 Cys45, and OTUD6B Cys158 (Figure 4 and
Figure S3). MS/MS analysis revealed potentially more UbPA
probe adduct sites, also on non-catalytic Cys residues as well as
non-DUB proteins, but systematic manual inspection of these
revealed insufficient confidence of assignment. It appears that the
reactivity of the probe propargyl moiety within DUBs critically
depends on the correct positioning identical to the scissile
isopeptide bond, which reduces potential “off-target” reactions
observed with Ub-probes carrying Michael acceptors or alkyl
halides (Hewings et al., 2018). Despite the clear assignment
for some DUBs, this approach did not yield a comprehensive
overview of DUBs reactive to probe as there were experimental
limitations in the detection of tryptic peptides harboring the
DUB’s catalytic Cys residue, as for most DUBs, the peptide
length is unsuitable for LC-MS/MS detection. To overcome
this, probe variants with redox release mechanisms have been
developed to selectively release probe reactive DUBs, but this
was also restricted to a subset of DUBs (de Jong et al., 2017).
In our case, we reasoned that probe reactive DUBs could be
displaced through a direct competition using cysteine-reactive
agents such as N-methylmaleimide (NEM) or the pan-DUB
inhibitor PR-619 (Altun et al., 2011; Kramer et al., 2012).
FIGURE 5 | Active vs. non-active DUBs. Volcano plots showing a discrimination between cysteine-reactive and non-reactive DUBs by active-site labeling with
HA-UbPA in the presence and absence of N-ethylmaleimide (NEM, Left panel) and PR-619 (Right panel) (data from two biological replicates run in technical
duplicates). Displaced reactive DUBs are located in the upper left compartment ([probe alone]—[probe + NEM or PR619]), whereas non-reacting DUBs are left in the
lower center area.
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DUB-probe competition could be captured by a quantitative
ABP-MS experiment. To this end, ABP assays were performed
using HA-UbPA probe exposed to MCF7 cell extracts previously
treated with excess NEM, PR-619, or DMSO control, followed
by enrichment of labeled DUBS and quantitative LC-MS/MS
analysis (Figure 5). Most cysteine protease DUBs were competed
by NEM and PR-619, indicated by their location on the left
in the volcano plot with the exception of USP13, USP39,
and USP40. As expected, DUB members of the JAMM family
were not affected and therefore not displaced. Interestingly, we
observe that components of the 26S (e.g., PSMD7) and ATXN
network (ATXN2/2L/10) were unchanged, although DUBs that
are part of these complexes such as USP14 and ATXN3 are
competed away, suggesting flexible complex dynamics. As a
specificity control, we did not observe competition of other non-
Ub cysteine proteases within the same experimental conditions
(Figure S4). We concluded that some USPs may have low
or no enzymatic activity under these cellular conditions, as
can be monitored by our ABPP assay. For instance, USP13
may not directly react to the UbPA probe via an active
cysteine and that it only binds via the Ub scaffold in a non-
covalent fashion. Our results suggest that, at least under these
circumstances, USP13 appears to be mostly inactive (at least
toward the HA-UbPA probe) in an endogenous context where
cells are not activated in a particular way, although USP13
was shown to deubiquitylate RAP80 in the context of the
DNA damage response (Li et al., 2017). USP39 is a DUB in
which the catalytic residue Cys 234 is replaced by an Asp,
FIGURE 6 | MCF7 DUB activitome vs. transcriptome and proteome. Scatter Plots showing the correlative traits of the transcriptome (A) and the proteome (B) with
the DUB activitome (X-axis in both panels). DUBs are indicated in colors respective to their enzyme sub-families.
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His 513 by Ser, and Asp 530 by a Glu. Its role in pre-mRNA
splicing and regulation of Aurora mRNA seems therefore not
dependent on catalytic activity (van Leuken et al., 2008). USP40
appears to be catalytically inactive in vitro despite having all
the catalytic residues proposed to be important for the catalytic
activity (Quesada et al., 2004). To gain further insight, we
examined how activity correlates with expression. To do this,
we compared the different data sets (Figure 6). DUBs identified
from 5,761 quantified protein groups that directly matched
to genes and mRNA transcripts (Table S1) were compared
to the expanded DUB “activitome” (Table S2), resulting in a
three-way comparison of DUB probe-based activity levels with
their mRNA (Figure 6A) and protein level (Figure 6B and
Table S3). Interestingly, DUB proteome intensities correlated
relatively well with the ones from the active DUBome. This
is perhaps due to the high affinity of the probe to the target,
meaning that more abundant enzymes will have better/faster
access to the probe, and they will probably react with it even
when their activity is not as high as other less abundant
enzymes. Comparing our expanded ABPP approach to the
DUB proteogenomic data sets, we could identify six DUBs
that were not present in the deep proteome data (CYLD,
OTUD1, OTUD7A, USP12, USP2, and USP45; Figures S1, S2B),
highlighting the importance of studying the active DUBome
over regular expression studies. On the other hand, no members
of the MINDY and ZUFSP families and most metalloprotease
DUBs (JAMMS) are present in our active DUBome data. JAMMs
DUBs are not supposed to react with the ABP probes utilized
due to the incompatibility of the reaction mechanism of the
probe to metalloproteases, and MINDY and ZUFSP proteins do
not seem to be expressed in the studied cell line. Since adding
a pre-fractionation step helped to get a better representation
of the DUBs, we also were able to obtain information about
different DUB isoforms. For instance, for USP28, three isoforms
produced by alternative splicing have been described (UniProt),
from which unique tryptic peptides were assigned to isoform
1 and 2 (Figure S5). For OTUD4, four isoforms have been
described to be produced by alternative splicing (UniProt). We
FIGURE 7 | Expanded panel of active DUBs across the different enzyme subfamilies. ML (maximum likelihood) phylogenetic tree of the human DUB family. One
hundred and two DUBs of the ubiquitin specific protease (USP), ubiquitin C-terminal hydrolases (UCH), ovarian tumor domain (OTU), JAMM, MINDY, JOS, and ZUP1
families are shown. In bold are the DUBs detected in the cellular proteome by active-site labeling, indicating cellular activity. *indicates inactive DUBs, in part because
of mutated catalytic site cysteines and **indicates selective induction by type I interferon (IFN). The gene name nomenclature was used for consistency, but many
DUBs have alternative names: ZA20D1 (OTU7B), YOD1 (OTU1/DUBA8), TNFAIP3 (OTUD7C/A20), AMSH (STAMBP1), AMSH-like (STAMBPL1), TL132 (USP32P2),
TL132-like (USP32P1), LOC339799 (EIF3FP3), ZRANB1 (TRABID), PSMD14 (RPN11/POH1), USP17L2 (DUB3), OTUD6B (DUBA5, CGI-77), and PAN2 (USP52). In
bold are those DUBs detected in the proteome, and the (*) indicates DUBs reactive to UbPA probe.
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have detected unique peptides for isoforms 1 and 2, suggesting
that they are expressed at the protein level. Interestingly, at the
transcriptomics level, an OTUD4P1 pseudogene was detected
at high levels, but not the original OTUD4 mRNA (Figure 1
and Table S1). USP15 has been characterized as expressed in
four isoforms, from which isoforms 2 and 4 were confirmed
at the protein level. USP47 isoform 1 shares peptides with the
other forms and so was not distinguishable, but transcriptomics
confirms expression of its cognate mRNA (Table S1). USP48 is
expressed as eight isoforms generated by alternative splicing,
from which we confirm the detection of unique peptides
corresponding to isoform 1 and a shorter version referred to
as A0A0A0MRS6-1 (UniProt) (Figure S5). The biological role
of these isoforms is not currently understood, but mutations in
USP48, potentially affecting the different isoforms differently,
have been associated with Cushing’s disease (Chen et al., 2018).
The function of different DUB isoforms can be quite distinct,
such as USP35, whose isoform 1 is an anti-apoptotic factor
that inhibits staurosporine- and TNF-related apoptosis-inducing
ligand (TRAIL). In contrast, USP35 isoform 2 associates to the
endoplasmic reticulum (ER) and is also present at lipid droplets
(Leznicki et al., 2018). Another case is USP7, for which two
isoforms USP7/USP7S were described that differentially bind to
Herpes virus protein and are also phosphorylated not in the same
manner, affecting the degradation rate of USP7S independently
of USP7 (Khoronenkova et al., 2012). For neither USP35 nor
USP7 can we detect unique peptides that would discriminate
between these isoforms at the protein level. Together, when
we combine the sets of DUB proteomic, transcriptomic, and
activitomic profiles, we are extending the global cellular DUB
landscape in terms of expression and evidence for enzymatic
activity (Figure 7). Generally, DUB active-site labeling was better
reflected by protein abundance as compared to mRNA levels.
Marked exceptions were OTUD4, USP35, USP2, USP21, and
CYLD that were all detected by probe labeling, but not at
the protein level, indicating very low levels of expression.
The extended ABPP profiles provide deeper insights, such as
detecting low abundant DUBs, such as USP2, USP21, USP12,
USP46, and USP35 that have previously been challenging
to be within the detection range (Table S3 and Figure S2B).
Our study sets the framework for a better understanding of
how physiological and pharmacological interferences affect the
DUB enzyme family and their biological pathways at a global
scale. Furthermore, it will help to accelerate the development
of high-throughput ABP assays with a greater breadth of
selectivity panel and tomonitor critical DUBs relevant for human
disease, as biomarkers or targets for disease modulation in a
clinical context.
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